Side-by-side comparison of AI visibility scores, market position, and capabilities
Reached $1B valuation (2026). Automates specialty drug prior auth, access barriers, and copay assistance for providers. Targets $500B+ specialty drug access bottleneck.
Tandem is a specialty drug access automation platform that has reached a $1 billion valuation in 2026, providing AI-powered automation of the full specialty pharmaceutical access workflow for healthcare providers — prior authorization submissions, access barrier management, copay assistance enrollment, and patient assistance program identification. The platform targets the $500+ billion specialty drug market where access friction is the primary barrier preventing patients from receiving prescribed medications.
Benchling is a life sciences R&D cloud platform with ~$200M+ ARR. Series E startup valued at ~$6.1B. Trusted by Pfizer, Genentech, and 1,000+ biotech/pharma teams. HQ: San Francisco.
Benchling is a cloud-based research and development platform purpose-built for the life sciences industry, founded in 2012 by Sajith Wickramasekara and Ashu Singhal as a Y Combinator alumnus. The company offers an integrated suite of tools including electronic lab notebooks (ELN), laboratory information management systems (LIMS), molecular biology design tools, and data management platforms, all connected in a unified cloud environment.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.